Browse studies

Find your next paid study

4,613 recruiting studies matching your filters

The Impact of Osteopathic Manipulative Treatment on Pelvic Floor Dysfunction, Activity, and Gait in Female Runners

This study will examine whether osteopathic manipulative treatment (OMT) affects pelvic floor symptoms, physical activity, and running gait in female runners. …

Pelvic Floor Disfunction

Estimated

~$10 – $7,500

Elizabeth PerreroNCT07812285

Prospective Cohort Study Comparing Sensory Outcome, Development of Chronic Pain and Phantom Pain, as Well as Patient Satisfaction in Cancer and Transgender Patients Undergoing Mastectomy and Reconstruction With and Without Reinnervation.

During breast surgery, sensory nerves are cut which may lead to reduced sensation and pain. Surgical reinnervation techniques have been developed with the aim …

Sensation DisordersSensation, PhantomPain, Postoperative+6 more

Estimated

~$10 – $750

Weill Medical College of Cornell UniversityNCT06094257

Phase 2

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemother…

Untreated, Unresectable, or Metastatic Colorectal Cancer

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07221357

Phase 1

A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers wi…

Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+8 more

Estimated

~$10 – $8,750

Tyra Biosciences, IncNCT06915753

Phase 2

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses With Placebo as Treatment for Rhinovirus (RV) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the seve…

Rhinovirus Infection

Estimated

~$10 – $8,750

Altesa Biosciences, Inc.NCT07610395

Phase 1

A Phase Ia/Ib Study of the Combination of the FGFR Inhibitor Pemigatinib and the EGFR Inhibitor Afatinib in Advanced Refractory Solid Tumors

This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid t…

Advanced Solid TumorUnresectable Solid TumorMetastatic Solid Tumor+1 more

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06302621

Phase 3

A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and…

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Estimated

~$10 – $8,750

Altimmune, Inc.NCT07795164

Phase 2

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compare…

Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

Estimated

~$10 – $8,750

CatalYm GmbHNCT07219459

Phase 1

Open-label Randomized, Three-fold Cross-over, Single-center Interaction Study to Investigate the Influence of Multiple Doses of Acetylsalicylic Acid (ASA) (Aspirin) on the Pharmacodynamics of BAY 3389934 in Healthy Participants.

The study treatment BAY3389934 is under development for people with blood clotting problems that occur due to sepsis. Sepsis is a serious condition that happen…

Drug-drug Interaction

Precise Oncology Interventions in Nutrition and Training (OnPoint)

The purpose of this study is to see if survivors of breast, prostate, colorectal or lymphoma cancer who receive a personal referral to a targeted nutrition and…

Breast CancerProstate CancerColorectal Cancer+1 more

Estimated

~$10 – $6,250

University of MiamiNCT06534918

Phase 3

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (CLAD) Following Bilateral Lung Transplantation

This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety o…

Lung Transplant Rejection

A Phase 1 Study of the STING Agonist CRD3874-SI for Relapsed and Refractory Acute Myeloid Leukemia

The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).

Acute Myeloid LeukemiaAMLRefractory Acute Myeloid Leukemia

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07661095